Petra Budde 1 , Jennifer Marte 2 , Hans-Dieter Zucht 1 , Saurabh Bhandari 1 , Manuel Tuschen 1 , Peter Schulz-
Knappe 1 , Ravi Madan 2 , Jeffrey Schlom 2 , and James Gulley 2 , EULAR 2018
Conclusions
- AABs that target proteins involved in cancer signaling, apoptosis, or cell cycle pathways are
associated with irAEs following prostvac/ipilimumab combination therapy. - In contrast, AABs targeting immune response pathways were found in patients who do not
develop irAEs and may counteract the action of inflammatory molecules. - Similarly, anti-cytokine AABs have been found in autoimmune diseases, were they appear to
counteract the effects of cytokines (4). Further studies in larger sample sets are needed to
confirm these findings.